No abstract

The effect of different concentrations of rocuronium bromide used for anesthesia induction during thyroid surgery on the intraoperative recurrent laryngeal nerve monitoring was evaluated. One hundred patients undergoing thyroid operation were randomized into five groups (20 patients per group). Patients in group I were operated and monitored without the use of rocuronium bromide. Patients in groups II-V were respectively injected with 0.5x, 1x, 1.5x, and 2x ED95 rocuronium bromide intravenously. The time from injecting the rocuronium bromide to the beginning of tube insertion was recorded, the conditions of tracheal intubation were evaluated, and the changes in blood pressure and pulse during the intubation process were monitored. Vagus nerve/recurrent laryngeal nerve evoked muscle potential was monitored using the NIM-Response3.0 nerve electromyography monitor. The amplitude of electromyography signal was recorded every 5 min during 30 min after successful tracheal intubation. The tracheal intubation success rate was 100% in all groups. Compared with group I, intubating condition scores (Cooper scores) in the patients of groups II-V were higher (P < 0.05). The stability of intraoperative neuromonitoring signal amplitude in groups I-III met the monitoring standards. The findings suggest that the use of 0.5x or 1x ED95 rocuronium bromide during the anesthesia induction can improve the tracheal tube conditions without affecting the intraoperative recurrent laryngeal nerve monitoring. The use of 1x ED95 rocuronium bromide induction was associated with the best results.

Abstract. Colorectal carcinoma (CRC) is a malignant solid tumor arising from the large intestine and is associated with an increasing incidence and poor prognosis. Further understanding of the molecular mechanisms underlying CRC may contribute to the development of novel effective therapeutic strategies. MicroRNAs (miRs), including miR-155, have been reported to be associated with the etiology and biology of CRC; however, the molecular mechanisms by which miR-155 affect CRC remain to be fully elucidated. The present study used a multidisciplinary approach, involving reverse transcription-quantitative polymerase chain reaction, northern blotting, MTT assay, cell cycle progression analysis, immunoblotting, and animal experiments, to determine the possible targets of miR-155 in CRC cells. miR-155 was found to be overexpressed in CRC tissue samples, compared with paired normal colon tissue samples. In addition, the inhibition of miR-155 induced a deceleration in CRC cell proliferation and inactivation of the Wnt/β-catenin signaling pathway. miR-155 suppression also reduced the growth of CRC xenografts in an animal model. HMG-box transcription factor 1 (HBP1) was identified as a novel target of miR-155, which mediated its effect on CRC via the Wnt/β-catenin pathway. Furthermore, patients with CRC exhibiting higher serum levels of miR-155 exhibited reduced survival rates. In conclusion, the present study demonstrated that miR-155 may contribute to the progression and growth of CRC by enhancing the Wnt/β-catenin pathway in an HBP1-associated mechanism. Therefore, miR-155 may be considered a promising therapeutic target for the treatment of CRC.